|Bid||21.050 x 4000|
|Ask||21.110 x 800|
|Day's Range||20.660 - 21.160|
|52 Week Range||12.890 - 21.200|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.58|
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced the initiation of a Phase IIIb clinical trial evaluating the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms in addition to pain, including bloating and discomfort, in adult patients with irritable bowel syndrome with constipation (IBS-C). Linaclotide is a guanylate cyclase-C (GC-C) agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC).
Short interest is high for IRWD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting IRWD. The net inflows of $2.72 billion over the last one-month into ETFs that hold IRWD are not among the highest of the last year and have been slowing.
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / U.S. markets were mixed Friday, with the Dow snapping an eight day losing streak as energy shares rallied. However, major indexes experienced weekly losses on ...
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today presented additional data from an exploratory Phase IIa study of praliciguat (IW-1973) in patients with type 2 diabetes and hypertension during an oral session at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Fla. Praliciguat is an oral, once-daily soluble guanylate cyclase (sGC) stimulator that is currently being studied in Phase II clinical trials in patients with diabetic nephropathy and in patients with heart failure with preserved ejection fraction (HFpEF). Building on previously announced top-line data from the Phase IIa randomized, placebo-controlled, 14-day study, which showed that treatment with praliciguat led to reductions in blood pressure, fasting plasma glucose, cholesterol levels and triglycerides in patients on a stable regimen of medicines to manage their disease, the newly reported findings also suggested that praliciguat improved insulin sensitivity.
Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD). Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors (PPIs), the current standard of care. “We are excited to advance development of IW-3718 by initiating the Phase III trials,” said Christopher Wright, M.D., Ph.D., senior vice president, global development and chief development officer at Ironwood.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotechnology company, today announced that the company will present clinical and preclinical data for the company’s soluble guanylate cyclase (sGC) stimulator praliciguat (IW-1973) during the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Fla., June 22 through June 26, 2018. Praliciguat is currently being studied in Phase II clinical trials in patients with diabetic nephropathy and in patients with heart failure with preserved ejection fraction (HFpEF). Data from a Phase IIa 14-day study of praliciguat in patients with diabetes and hypertension will be featured as an oral presentation during the Emerging Targets for Diabetes Treatment session, presented by John P. Hanrahan, M.D., M.P.H., of Ironwood.
LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on IRWD sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com observes the recent performance of Horizon Pharma PLC (NASDAQ: HZNP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Lipocine Inc. (NASDAQ: LPCN), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on June 7) Baxter International Inc (NYSE: BAX ) Bio-Rad Laboratories, ...
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to olinciguat (IW-1701) for the treatment of patients with sickle cell disease. Olinciguat is an orally administered soluble guanylate cyclase (sGC) stimulator. “There is an urgent need for new, innovative treatments for patients with sickle cell disease, a debilitating and potentially fatal inherited blood disorder that causes painful crises, organ damage and other serious complications,” said Christopher Wright, M.D., Ph.D., senior vice president of global development and chief development officer.
Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13th, 2018 at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at the Terranea Resort in Rancho Palos Verdes, California. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.
Ironwood Pharmaceuticals, Inc. , a commercial biotech company, today presented data from a double-blind, placebo-controlled, dose-ranging Phase IIb trial evaluating IW-3718 in persistent gastroesophageal reflux disease during a distinguished abstract plenary oral session at Digestive Disease Week® 2018 in Washington, D.C. The data demonstrated that, compared to placebo, IW-3718 1500 mg plus a once ...
Ironwood Pharmaceuticals (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood Pharmaceuticals shareholders have rejected an attempt by activist investor Alex Denner to join the Cambridge drugmaker’s board, the company announced Thursday. Ironwood (Nasdaq: IRWD) said that shareholders at its annual meeting had voted to elect three independent directors who were up for re-election. The company had lobbied for that result in recent weeks and strongly opposed the election of Denner, who is known for orchestrating sales of local biotechs.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced that, based on the vote count following the 2018 Annual Meeting of Shareholders, shareholders voted to re-elect all three of Ironwood’s director nominees: Lawrence Olanoff, M.D., Ph.D., Amy Schulman and Douglas Williams, Ph.D. On behalf of the entire Ironwood Board of Directors and management team, we thank our shareholders for their valuable insights and support over these past several weeks.
GREENWICH, Conn. , May 31, 2018 /PRNewswire/ -- Sarissa Capital Management LP today made the following statement regarding Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). We believe the plan to separate ...
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotechnology company, today announced that the company in collaboration with researchers will present clinical data for IW-3718 during Digestive Disease Week (DDW) in Washington D.C., June 2 through June 5, 2018. One of the abstracts will be presented at the Distinguished Abstract Plenary Session. During this session, Michael Vaezi, Ph.D., M.D., of Vanderbilt University will share Phase IIb data on the effect of IW-3718 on heartburn and regurgitation – the two most frequent and bothersome symptoms of gastroesophageal reflux disease (GERD)1 – in patients with persistent GERD despite treatment with proton pump inhibitors (PPIs).
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced that it has mailed a letter to shareholders highlighting the experience and personal perspectives of the company’s director nominees: Lawrence Olanoff, M.D., Ph.D., Amy Schulman and Douglas Williams, Ph.D. The Ironwood Board of Directors strongly recommends that shareholders vote on the WHITE proxy card “FOR” Ironwood’s experienced, diverse and independent nominees. Ironwood’s letter to shareholders and other materials regarding the Board’s recommendation for the 2018 Annual Meeting can be found at www.ironwoodannualmeeting.com.
NEW YORK, NY / ACCESSWIRE / May 10, 2018 / U.S. markets spiked Wednesday as strong performances by the energy, financials and technology sectors lifted the major indexes higher. The Dow Jones Industrial ...
Commercial stage biopharma company Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD )'s Linzess, which it markets along with Allergan plc (NYSE: AGN ) in the U.S., is a major revenue earner for the company. ...
Ironwood Pharmaceuticals, Inc.(IRWD), a commercial biotech company, today announced that it filed an investor presentation with the Securities and Exchange Commission in connection with the company’s Annual Meeting of Shareholders scheduled for May 31, 2018.
NEW YORK, May 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CASI ...